7 June 2024 in Rheumatology Advances in Practice
Objectives: To investigate whether circulating endothelial protein C receptor (EPCR) is associated with disease activity and inflammatory markers in rheumatoid arthritis. Methods: Thirty-eight RA patients and 21 healthy controls (HC) were recruited via the A3BC biobank. Peripheral blood mononuclear cells and plasma were isolated from the blood of these participants. Plasma soluble (s)EPCR, IL-6, IL-17 and sCD14 were measured by enzyme-linked immunosorbent assay, cell membrane-associated (m)EPCR by flow cytometry; EPCR gene H3 single nucleotide polymorphism (SNP), which contributes to high plasma sEPCR levels, by PCR and DNA sequencing. Data were analysed using FlowJo10 and GraphPad Prism 10. Results: RA patients had higher levels of mEPCR on T cells and plasma sEPCR compared with HC. No difference in the EPCR gene H3 SNP G genotype frequency was found between RA and HC. This SNP was significantly correlated with higher sEPCR levels in HC but not in RA patients. In RA, plasma sEPCR levels were positively correlated with IL-6, IL-17, sCD14, anti-CCP and rheumatoid factor. In contrast, mEPCR levels on T cells and natural killer cells (NK) were inversely associated with disease activity measures including 28/66 swollen joint count, 28/68 tender joint count and/or DAS28-CRP/ESR scores, and positively correlated with EPCR gene H3 SNP, which was also correlated with lower disease activity measures in RA. Conclusion: Our findings suggest that EPCR may play an important role in RA, with plasma sEPCR being potentially associated with inflammatory markers and mEPCR and the EPCR gene H3 SNP possibly related to disease activity measures.
1 January 2025 in Advanced Gut & Microbiome Research
Objective: Rheumatoid arthritis (RA) is a common musculoskeletal condition with an estimated prevalence of 0.27% in Australia and New Zealand. Recently, interest in the role of the human microbiome regarding RA pathogenesis has increased. This study is aimed at determining the composition of the stool and oral microbiome of RA patients taking common disease‐modifying antirheumatic drugs (DMARDs). Methods: For this cross‐sectional study, RA patients ( n = 28) with established disease (> 12 months since diagnosis) and healthy individuals ( n = 10) were recruited by the Australian Arthritis and Autoimmune Biobank Collaborative (A3BC). Stool samples and oral swabs were collected, processed, and sequenced to obtain 16s rRNA amplicon sequencing data. Data was processed using a QIIME2/DADA2 pipeline. Diversity and taxonomic analyses were performed using QIIME2 core metrics functions and RStudio packages. Results: Diversity analyses identified differences in the RA stool microbiome, in comparison to healthy controls and between RA patients taking different DMARDs. This includes differences in microbial richness, diversity, and structure. For example, the microbiome of patients taking JAK inhibitors (JAKis) significantly differed to the microbiome of patients on combination therapy (TNF inhibitors [TNFi] +/− methotrexate [MTX]) or taking MTX only. Furthermore, patients taking MTX had a more similar microbiome to healthy individuals. In contrast, limited differences in the oral microbiome were observed for all diversity metrics, although a number of taxa previously linked to oral disease were identified as differentially abundant to healthy individuals. Conclusion: Differences in the diversity and taxa of the stool and oral microbiome of patients with established RA were identified. Overall, there was some concordance with previous research. This work highlights the importance of further investigation into the impact of JAKi, TNFi, and MTX on the RA microbiome.